Global Bovine Respiratory Disease Treatment Market
According to the report " Bovine Respiratory Disease Treatment Market ", published by Market Data Forecast, the global market is projected to reach USD 67.31 Million by 2021, at a CAGR of 22.4 % from 2016 to 2021.
BRD refers to any disease of the lower or upper respiratory tracts in cattle and is commonly associated with lung infections, which can cause pneumonia. The disease is the most common and costliest problem encountered in stocker or feedlot calves.
The risk of bovine respiratory disease( BRD) has a significant effect on the value of cattle in the marketplace. Bovine respiratory disease can be a costly expense for cattle producers. It causes major economic losses to the producer by reducing average daily gain, feed efficiency, and overall performance of beef calves.
Global Bovine Respiratory Disease Treatment Market is segmented as follows.
1. By Type of Treatment: �
� � � � �
Anti-Infectious Agents a) Antibiotics b) Sulfas Anti-Parasiticides Bronchodilators Oral Rehydration Fluids Non-Steroidal Anti-Inflammatories Mucolytics
2. By Geography:
� � � � �
North America Europe Asia-Pacific Latin America Middle-East and Africa
The major companies dominating this market by their products and services are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S. A. S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S. A, Ceva Sante Animale and Vétoquinol S. A.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
+ 1 888-702-9626 | www. marketdataforecast. com | contact @ marketdataforecast. com